[go: up one dir, main page]

BRPI0818193A2 - compound, pharmaceutically acceptable salt of a compound, pharmaceutical composition, and use of a compound - Google Patents

compound, pharmaceutically acceptable salt of a compound, pharmaceutical composition, and use of a compound

Info

Publication number
BRPI0818193A2
BRPI0818193A2 BRPI0818193A BRPI0818193A BRPI0818193A2 BR PI0818193 A2 BRPI0818193 A2 BR PI0818193A2 BR PI0818193 A BRPI0818193 A BR PI0818193A BR PI0818193 A BRPI0818193 A BR PI0818193A BR PI0818193 A2 BRPI0818193 A2 BR PI0818193A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
pharmaceutical
Prior art date
Application number
BRPI0818193A
Other languages
Portuguese (pt)
Inventor
Kawamura Asuka
Shimada Kousei
Arakawa Naohisa
Domon Yuki
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to BR122013020635-3A priority Critical patent/BR122013020635A2/en
Publication of BRPI0818193A2 publication Critical patent/BRPI0818193A2/en
Publication of BRPI0818193B1 publication Critical patent/BRPI0818193B1/en
Publication of BRPI0818193B8 publication Critical patent/BRPI0818193B8/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/613Unsaturated compounds containing a keto groups being part of a ring polycyclic
    • C07C49/617Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system
    • C07C49/623Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system having two rings
    • C07C49/627Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system having two rings the condensed ring system containing seven carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/32Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/20All rings being cycloaliphatic the ring system containing seven carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/93Spiro compounds
    • C07C2603/94Spiro compounds containing "free" spiro atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0818193A 2007-09-28 2008-09-25 compound, pharmaceutical composition, and use of a compound BRPI0818193B8 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122013020635-3A BR122013020635A2 (en) 2007-09-28 2008-09-25 COMPOUND

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007-255430 2007-09-28
JP2007255430 2007-09-28
PCT/JP2008/067223 WO2009041453A1 (en) 2007-09-28 2008-09-25 Bicyclic γ-amino acid derivative

Publications (3)

Publication Number Publication Date
BRPI0818193A2 true BRPI0818193A2 (en) 2017-12-12
BRPI0818193B1 BRPI0818193B1 (en) 2020-11-10
BRPI0818193B8 BRPI0818193B8 (en) 2021-05-25

Family

ID=40511336

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0818193A BRPI0818193B8 (en) 2007-09-28 2008-09-25 compound, pharmaceutical composition, and use of a compound
BR122013020635-3A BR122013020635A2 (en) 2007-09-28 2008-09-25 COMPOUND

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122013020635-3A BR122013020635A2 (en) 2007-09-28 2008-09-25 COMPOUND

Country Status (25)

Country Link
US (1) US7947738B2 (en)
EP (2) EP2192109B1 (en)
JP (1) JP4479974B2 (en)
KR (2) KR101409079B1 (en)
CN (2) CN103483169A (en)
AU (1) AU2008304933B2 (en)
BR (2) BRPI0818193B8 (en)
CA (1) CA2701110C (en)
CO (1) CO6270314A2 (en)
CY (1) CY1114836T1 (en)
DK (1) DK2192109T3 (en)
ES (2) ES2531324T3 (en)
HR (1) HRP20130935T1 (en)
IL (1) IL204621A (en)
MX (1) MX2010003394A (en)
MY (2) MY153910A (en)
NZ (1) NZ584699A (en)
PH (1) PH12013501663B1 (en)
PL (1) PL2192109T3 (en)
PT (1) PT2192109E (en)
RU (1) RU2446148C2 (en)
SI (1) SI2192109T1 (en)
TW (2) TWI436762B (en)
WO (1) WO2009041453A1 (en)
ZA (1) ZA201002013B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2531324T3 (en) 2007-09-28 2015-03-13 Daiichi Sankyo Co Ltd Intermediate to produce a bicyclic gamma-amino acid derivative
WO2010079668A1 (en) * 2009-01-08 2010-07-15 第一三共株式会社 Olefin compound
WO2010110361A1 (en) 2009-03-26 2010-09-30 第一三共株式会社 Method for producing bicyclic γ-amino acid derivative
ES2649968T3 (en) * 2011-06-08 2018-01-16 Daiichi Sankyo Company, Limited Production procedure of a bicyclic compound via Claisen transposition
BR112013031360B1 (en) * 2011-06-08 2022-01-25 Daiichi Sankyo Company, Limited Method to make a compound
CA2859003C (en) * 2011-12-15 2016-11-01 Daiichi Sankyo Company, Limited Optical resolution method for bicyclic compound using asymmetric catalyst
WO2013089189A1 (en) * 2011-12-16 2013-06-20 第一三共株式会社 Optical resolution method for bicyclic compound using hydroxysulfonic acid
EP2813513B1 (en) * 2012-02-08 2019-07-03 Stella Pharma Corporation Method for producing cereulide and derivative thereof, intermediate for production of cereulide, and cereulide derivative
KR101976891B1 (en) * 2012-04-10 2019-05-09 다이이찌 산쿄 가부시키가이샤 Optical resolution method for bicyclic compound using enzyme
IN2014MN02116A (en) 2013-04-04 2015-09-04 Daiichi Sankyo Companyltd
TWI635071B (en) * 2013-07-08 2018-09-11 第一三共股份有限公司 OPTICALLY ACTIVE BICYCLIC γ-AMINO ACID AND PREPARATION METHOD FOR THE SAME
JP6491213B2 (en) * 2013-12-18 2019-03-27 ノヴァッセイ エスエー Gamma-aminobutyric acid (GABA) analogs for the treatment of pain and other disorders
BR112017019920B1 (en) 2015-03-19 2023-11-07 Daiichi Sankyo Company, Limited SOLID PHARMACEUTICAL PREPARATION, AND METHOD FOR STABILIZING A SOLID PHARMACEUTICAL PREPARATION
US10561628B2 (en) 2015-03-19 2020-02-18 Daiichi Sankyo Company, Limited Solid preparation including antioxidant
CN107848953B (en) * 2015-12-25 2021-05-18 四川海思科制药有限公司 Condensed ring γ-amino acid derivative, preparation method and medical application thereof
WO2017114225A1 (en) * 2015-12-31 2017-07-06 四川海思科制药有限公司 Fused tricyclic γ-amino acid derivative and preparation method and pharmaceutical application thereof
CN106928080B (en) * 2015-12-31 2020-12-25 四川海思科制药有限公司 Fused ring gamma-amino acid derivative, preparation method and application thereof in medicine
WO2017183539A1 (en) * 2016-04-18 2017-10-26 第一三共株式会社 Method for producing bicyclic compound using meldrum's acid
TW201806928A (en) * 2016-07-01 2018-03-01 第一三共股份有限公司 Crystals of aminocarboxylic acid acid addition salts and the synthetic method thereof
ES2906887T3 (en) * 2016-07-21 2022-04-20 Chia Tai Tianqing Pharmaceutical Group Co Ltd Indole derivative used as a CRTH2 inhibitor
MY196788A (en) * 2016-09-14 2023-05-03 Sichuan Haisco Pharmaceutical Co Ltd Fused tricyclic ?-amino acid derivative, preparation method therefor, and medical use thereof
JP7051332B2 (en) * 2017-08-23 2022-04-11 キヤノン株式会社 Organic compounds and photoelectric conversion elements
TW202019871A (en) * 2018-07-12 2020-06-01 大陸商四川海思科製藥有限公司 Crystal form of salt of fused tricyclic [gamma]-amino acid derivative and preparation and use thereof
MX2021000403A (en) 2018-07-12 2021-03-25 Sichuan Haisco Pharmaceutical Co Ltd COMPOSITION OF FUSIONED GAMMA TRICYCLIC AMINO ACID DERIVATIVES AND THE PREPARATION THEREOF.
BR112021001008A2 (en) * 2018-07-30 2021-04-20 Daiichi Sankyo Company, Limited drug tablet
CN112384493B (en) * 2018-08-09 2023-06-06 四川海思科制药有限公司 Preparation method and intermediate of fused tricyclic γ-amino acid derivatives
WO2021043117A1 (en) * 2019-09-03 2021-03-11 四川海思科制药有限公司 Impurity detection method for 2-((1s,2s,3r,6s,8s)-2-(aminomethyl)tricyclo[4.2.1.0 3,8]nonane-2-yl)acetate benzenesulfonate or composition thereof
CN110511141B (en) * 2019-09-09 2022-04-29 上海凌凯医药科技有限公司 Synthesis method of valproyl urea
US20220296548A1 (en) 2019-10-25 2022-09-22 Kyoto University Preventative or therapeutic agent for tauopathy
CN110818582B (en) * 2019-11-20 2023-06-09 合肥拓锐生物科技有限公司 GABA analogue and salt thereof, and synthetic method, application and medicine thereof
CN111116345A (en) * 2019-12-30 2020-05-08 上海华理生物医药股份有限公司 Novel method for preparing Mirogabalin
CA3216507A1 (en) 2021-05-12 2022-11-17 Boehringer Ingelheim International Gmbh Pyridine derivatives with c-linked cyclic substituents as cgas inhibitors
CN114195661B (en) * 2021-12-21 2023-12-22 苏州楚凯药业有限公司 Preparation method of milobalin benzenesulfonate
CN117986143A (en) * 2022-11-03 2024-05-07 中科中山药物创新研究院 Gamma-aminobutyric acid derivatives containing polycyclic structures and preparation methods and uses thereof
CN116903468B (en) * 2023-07-14 2024-01-26 山东新时代药业有限公司 Preparation method of milbelin intermediate
CN117623957A (en) * 2023-12-04 2024-03-01 中国药科大学 A diastereoisomer of milopaline besylate [(1R,5S,6R)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-ene-6- Synthetic method of benzenesulfonate acetate
CN117800858B (en) * 2023-12-28 2024-06-21 南京津泓科技有限公司 Preparation method for catalytic cyanation of milbelin
TW202535348A (en) * 2024-01-08 2025-09-16 大陸商海思科醫藥集團股份有限公司 Use of a fused tricyclic γ-amino acid derivative in treating central nervous system pathological pain
CN118420477B (en) * 2024-07-01 2024-10-29 中节能万润股份有限公司 Preparation method of milobalin benzenesulfonate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19547766A1 (en) * 1995-12-20 1997-06-26 Gruenenthal Gmbh 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as active pharmaceutical ingredients
US6635673B1 (en) 1997-10-27 2003-10-21 Warner-Lambert Company Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
HN2000000224A (en) 1999-10-20 2001-04-11 Warner Lambert Co BICYCLE AMINO ACIDS AS PHARMACEUTICAL AGENTS
GB2374595A (en) * 2001-04-19 2002-10-23 Warner Lambert Co Fused bicyclic or tricyclic amino acids
DE60235619D1 (en) * 2001-04-19 2010-04-22 Warner Lambert Co CONCENTRATED BICYCLIC OR TRICYCLIC AMINO ACIDS
JP2005536507A (en) 2002-07-11 2005-12-02 メルク エンド カムパニー インコーポレーテッド Treatment of neuropathic pain with 6H-pyrrolo [3,4-d] pyridazine compounds
GB0223072D0 (en) * 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
ES2531324T3 (en) 2007-09-28 2015-03-13 Daiichi Sankyo Co Ltd Intermediate to produce a bicyclic gamma-amino acid derivative

Also Published As

Publication number Publication date
CN101878193B (en) 2014-07-09
JP4479974B2 (en) 2010-06-09
EP2657219B1 (en) 2014-12-10
IL204621A0 (en) 2010-11-30
EP2192109A1 (en) 2010-06-02
HK1139381A1 (en) 2010-09-17
MY172034A (en) 2019-11-12
HK1190698A1 (en) 2014-07-11
EP2657219A1 (en) 2013-10-30
WO2009041453A1 (en) 2009-04-02
HRP20130935T1 (en) 2013-11-22
RU2446148C2 (en) 2012-03-27
TW200924743A (en) 2009-06-16
CY1114836T1 (en) 2016-12-14
SI2192109T1 (en) 2014-03-31
CA2701110A1 (en) 2009-04-02
CA2701110C (en) 2013-01-08
BRPI0818193B8 (en) 2021-05-25
NZ584699A (en) 2011-04-29
CN103483169A (en) 2014-01-01
RU2010116708A (en) 2011-11-10
BRPI0818193B1 (en) 2020-11-10
ES2433890T3 (en) 2013-12-12
TWI436762B (en) 2014-05-11
ZA201002013B (en) 2010-11-24
KR20100065342A (en) 2010-06-16
PT2192109E (en) 2013-12-09
PH12013501663A1 (en) 2015-02-09
PH12013501663B1 (en) 2018-09-07
AU2008304933B2 (en) 2011-02-24
CO6270314A2 (en) 2011-04-20
KR101335784B1 (en) 2013-12-05
MX2010003394A (en) 2010-04-09
TW201439053A (en) 2014-10-16
AU2008304933A1 (en) 2009-04-02
BR122013020635A2 (en) 2019-08-06
IL204621A (en) 2013-04-30
ES2531324T3 (en) 2015-03-13
US20100249229A1 (en) 2010-09-30
CN101878193A (en) 2010-11-03
EP2192109B1 (en) 2013-09-04
MY153910A (en) 2015-04-15
TWI526425B (en) 2016-03-21
KR20130093181A (en) 2013-08-21
EP2192109A4 (en) 2012-04-18
JPWO2009041453A1 (en) 2011-01-27
PL2192109T3 (en) 2014-01-31
US7947738B2 (en) 2011-05-24
KR101409079B1 (en) 2014-06-18
DK2192109T3 (en) 2013-12-16

Similar Documents

Publication Publication Date Title
BRPI0818193A2 (en) compound, pharmaceutically acceptable salt of a compound, pharmaceutical composition, and use of a compound
BRPI0917540A2 (en) compound, pharmaceutically acceptable salt, pharmaceutical composition, and use of a pharmacologically acceptable compound or salt
BRPI0810696A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND
BRPI0810161A2 (en) COMPOUND, PHARMACEUTICAL PREPARATION, PHARMACEUTICAL COMPOSITION, AND USE OF A COMPOUND
BRPI1013988A2 (en) compound, pharmaceutical composition, and use of a compound or a pharmaceutically acceptable salt thereof
BRPI0919942A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND
BRPI0907562A2 (en) compound, pharmaceutical composition, and use of a compound
BRPI0921375A2 (en) compound, pharmaceutical composition, and use of a compound
BRPI0821115A2 (en) Aminotriazole-derived compound, drug, pharmaceutical composition and use of compound
BRPI0815709A2 (en) composition, pharmaceutical composition, and use of a compound.
BRPI0607545A2 (en) compound, use of a compound of formula I or a pharmaceutically acceptable salt thereof, and pharmaceutical composition
BRPI0819696A2 (en) Compounds of 2-phenylpyrimidine derivatives, pharmaceutical composition and use of a compound
BRPI0716171A2 (en) compound, pharmaceutical composition and use of a compound.
BRPI0917579A2 (en) compound, pharmaceutical composition, methods, and use of a compound
BRPI1016219A2 (en) compound, pharmaceutical composition, and use of a compound
BRPI1008793A2 (en) compound use of a compound and pharmaceutical composition
BRPI0609802A2 (en) compound, pharmaceutical composition and use of a compound
BRPI0921879A2 (en) compound, pharmaceutical composition, and use of a compound
BRPI0516609A (en) pharmaceutically acceptable compound or salt, hydrate, or stereoisomer thereof, pharmaceutical composition, and use of a compound
BRPI0812942A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION AND USE OF A COMPOUND
BRPI0810019A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND
BRPI0822033A2 (en) Compound or salt thereof, pharmaceutical composition, use of a compound or salt, and kit
BRPI1007018A2 (en) compound, pharmaceutical composition, and use of a compound.
BRPI0716698A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION AND USE OF A COMPOUND
BRPI1008906A2 (en) compound, pharmaceutical composition, and use of a compound.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/09/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF